Coexistence of Rheumatoid Arthritis and Familial Mediterrean Fever: A Case Report and Review of the Literature

Öz

Familial Mediterranean Fever (FMF) is the most prevalent monogenic autoinflammatory disease characterized by clinical features
of recurrent episodes of fever, leukocitosis, serositis, myalgia, erysipelas-like skin lesions, lasting 12-72 hours. Rheumatoid
arthritis (RA) is a chronic, systemic inflammatory disease. The most prominent feature is symmetrical pain and swelling of the
hands, wrists, feet, and knees. The exact mechanisms underlying the coexistence of FMF and RA has not been reported previously.
So far, only 8 cases of the coexistence of FMF and RA have been reported. In this report, we aimed to explain the association
between FMF and RA and report one more case of this coexistence. 

Anahtar Kelimeler

• fmf
• rhematoid artritis
• coexistence

Romatoid Artrit ve Ailevi Akdeniz Ateşinin Birlikteliği: Bir Olgu Sunumu ve Literatürün Gözden Geçirilmesi

Öz

Familial Mediterranean Fever (FMF) is the most prevalent monogenic autoinflammatory disease with clinical features of recurrent episodes of fever, leukocitosis, serositis, myalgia, erysipelas-like skin lesions, lasting 12-72 hours. Rheumatoid arthritis (RA) is a chronic, symmetrical, inflammatory autoimmune disease that affects small joints, eyes, heart, kidneys, and lungs. The exact mechanisms underlying the coexistence of FMF and RA has not reported previously. Also, so far, only 8 cases of the coexistence of FMF and RA have been reported. In this report we aimed to explain the association between FMF and RA and report one more case of this coexistence.

Anahtar Kelimeler

• coexistence
• familial mediterranean fever
• rheumatoid arthritis

Kaynakça

1. Silva-Fernández L, Macía-Villa C, Seoane-Mato D, et al. The prevalence of rheumatoid arthritis in Spain. Sci Rep. 2020;10:21551.
2. Ulrich Scherer H, Häupl T, Burmester GR. Journal of Autoimmunity. 2020;110:1024002.
3. Tufan A, Lachmann HJ. Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turk J Med Sci. 2020;50:1591-610.
4. Portincasa P. Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare. Curr Med Chem. 2016;23:60-86.
5. Turan Y, Şendur ÖF, Berkit IA. Coexistence of Familial Mediterranean Fever and Rheumatoid Arthritis in A Case. Turk J Rheumatol. 2010;25:44-6.
6. Mori S, Yonemura K, Migita K. Familial mediterranean fever occuring in an elderly Japanese woman with recent-onset rheumatoid arthritis. Intern Medicine. 2013;52:385-8.
7. Migita K, Abiru S, Sasaki O, et al. Coexistence of familial Mediterranean fever and rheumatoid arthritis. Mod Rheumatol. 2014;24:212-6.
8. Alpaycı M, Yazmalar L. Successful Treatment with Etanercept of Rheumatoid Arthritis Occurring in a Patient with Familial Mediterranean Fever. Turk J Phys Med Rehab. 2014;60:69-71.

9. Nureki SI, Ishii K, Fujisaki H, et al. Familial Mediterranean Fever With Rheumatoid Arthritis Complicated by Pulmonary Paragonimiasis. Intern Med. 2016;55:2889-92.
10. Gök K, Cengiz G,Erol K,Ozgocmen S. Tofacitinib Suppresses Disease Activity and Febrile Attacks in a Patient With Coexisting Rheumatoid Arthritis and Familial Mediterranean Fever. Acta Reumatol Port. 2017;42:88-90.
11. Matsuoka N, Iwanaga J, Ichinose Y, Fujiyama K, Tsuboi M, Kawakami A, Migita K. Two elderly cases of familial mediterranean fever with rheumatoid arthritis. Int J Rheum Dis. 2014;21:1873-7.
12. Koga T, Kawashiri SY, Migita K, et al. Comparison of serum inflammatory cytokine concentrations in familial Mediterranean fever and rheumatoid arthritis patients. Scand J Rheumatol. 2018;47:331-3.
13. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:1879-85.
14. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81. Yago T, Asano T, Fujita Y, Migita K.Fukushima J. Familial Mediterranean fever phenotype progression into anti-cyclic citrullinated peptide antibody-positive rheumatoid arthritis:a case report. Med Sci. 2020;66:160-6.
15. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res.2012;64:625-39.
16. Alayli G, Durmus D, Ozkaya O, Sen HE, Nalcacioglu H, Bilgici A, et al. Functional capacity, strength, and quality of life in children and youth with familial Mediterranean fever. Pediatr Phys Ther 2014;26:347-52.
17. Bodur H, Yurdakul FG, Duruoz MT, et al. Familial Mediterranean Fever: Health-Related Quality of Life and Associated Variables in a National Cohort. Archives of Rheumatology 36:159-66.
18. van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis 2017;76:4916.
19. Inanir A, Yigit S, Karakus N, Tekin S, Rustemoglu A. Association of MEFV gene mutations with rheumatoid factor levels in patients with rheumatoid arthritis. J Investig Med. 2013;61:593-6.